106147-84-6

Usage

Uses

Used in Research Applications:
(5-Methyl-1-trityl-1H-imidazol-4-yl)Methanol is used as a research compound for [application reason], such as studying its chemical properties, interactions with other molecules, or potential applications in various fields. Its unique structure and characteristics make it a valuable tool for scientific investigation.
Used in Pharmaceutical Research:
(5-Methyl-1-trityl-1H-imidazol-4-yl)Methanol is used as a pharmaceutical research compound for [application reason], such as exploring its potential as a drug candidate or its interactions with biological targets. The presence of the imidazole ring and other functional groups may provide insights into its potential therapeutic applications.
Used in Chemical Synthesis:
(5-Methyl-1-trityl-1H-imidazol-4-yl)Methanol is used as a chemical intermediate or building block in the synthesis of more complex molecules for [application reason], such as creating new drugs, materials, or other compounds with specific properties. Its unique structure may offer advantages in the synthesis process or contribute to the desired characteristics of the final product.

Upstream product

• 76-83-5 trityl chloride 
• 7487-88-9 magnesium sulfate 
• 38585-62-5 4-hydroxymethyl-5-methylimidazole hydrochloride 
• 29636-87-1 4⁽⁵⁾-methyl-5⁽⁴⁾-hydroxymethylimidazole 

Downstream Products

• 106147-86-8 4-(2,2-diphenylethyl)-5-methyl-1-tritylimidazole 
• 106147-59-5 4⁽⁵⁾-(2,2-diphenylethyl)-5⁽⁴⁾-methylimidazole 
• 698353-90-1 (2S,4E)-5-[5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]-2-[[(phenylmethoxy)carbonyl]amino]-4-pentenoic acid 1,1-dimethylethyl ester 
• 500782-76-3 C₂₈H₄₁N₅O₄ 
• 500782-75-2 C₄₇H₅₅N₅O₄ 
• 500782-74-1 C₄₇H₄₆N₄O₃ 
• 501010-05-5 C₂₄H₃₃N₅O₄ 
• 500783-14-2 C₄₃H₄₇N₅O₄ 
• 501010-23-7 C₂₄H₃₃N₅O₄ 
• 500783-08-4 C₄₃H₄₇N₅O₄ 
• 501010-21-5 C₂₄H₃₂FN₅O₄ 
• 500783-06-2 C₄₃H₄₆FN₅O₄ 
• 500783-04-0 C₄₇H₄₉N₅O₄ 
• 500783-02-8 C₃₅H₃₄N₄O 

Relevant academic research and scientific papers

Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I

A series of compounds based on the carboxyl-terminal CAAL sequence of PGGTase-I substrates was designed and synthesized. Using piperazin-2-one as a semi-rigid scaffold, we have introduced critical pharmacophores in a well-defined arrangement to mimic the CAAL sequence. High potency and exceptional selectivity were obtained for inhibition of PGGTase-I with structures such as 45 and 70. Potency of this series of GGTIs was dependent on the presence of an l-leucine residue with a free carboxyl terminus, as well as an S configuration of the 3-aryl group. The selectivity was significantly enhanced by 5-methyl substitution on the imidazole ring and fluorine substitution on the 3-aryl group. Modification of the 6-position of the piperazinone scaffold was found to be unfavorable. Compounds 44 and 69, the corresponding methyl esters of 45 and 70, were found to selectively block processing of Rap1A by PGGTase-I in whole cells with IC50 values of 0.4 M and 0.7 M respectively. The Royal Society of Chemistry 2006.

SSR182289A, a selective and potent orally active thrombin inhibitor

SSR182289A 1 is the result of a rational optimisation process leading to an orally active thrombin inhibitor. The structure incorporates an original 2-(acetylamino)-[1,1′-biphenyl]-3-sulfonyl N-terminal motif, a central L-Arg surrogate carrying a weakly basic 3-amino-pyridine, and an unusual 4-difluoropiperidine at the C-terminus. Its synthesis is convergent and palladium catalysis has been employed for the construction of the key C-C bonds: Suzuki coupling for the bis-aryl fragment and Sonogashira reaction for the δ-ε bond of the central amino-acid chain. The compound is a potent inhibitor of thrombin's activities in vitro and demonstrates potent oral anti-thrombotic potencies in three rat models of thrombosis. The observed in vitro potency could be rationalized through the examination of the interactions within the SSR182289A 1 - thrombin crystal structure. SSR182289A 1, has been therefore selected for further development.

Quinoxaline derivatives useful in therapy

Compounds of formula (I), wherein A represents N or CH; R1 and R2 independently represent C1-4 alkyl, halo or CF3 ; R3 represents C1-4 alkyl (optionally substituted), C3-7 cycloa

Synthesis and structure-activity of 4(5)-(2,2-diphenylethyl)imidazoles as new α2-adrenoreceptor antagonists

4(5)-(2,2-diphenylethyl)imidazole 6a is described as being a potent (pK(i) = 8.16 for displacement of [3H] p-aminoclonidine) and selective (selectivity = -log (pK(i) α2 - pK(i) α1) = 81) α2-adrenoreceptor antagonist (pA2 = 8.73 versus clonidine in the electrically stimulated guinea pig ileum) with additional activity as a norepinephrine uptake inhibitor (IC50 = 0.3 μM). An investigation of the structure-activity relationships of compounds closely related to 6a has been carried out. This included substitution of the phenyl and imidazole rings and modification of the link between these two ring systems. The various synthetic routes used are described. The affinity and the selectivity of the compounds for the α2 site were determined by studying the displacement of [3H] p-aminoclonidine and [3H] WB-4101 from rat forebrain membranes. The efficacy of the compounds was defined by measuring the antagonism of the clonidine effect on the electrically stimulated guinea pig ileum.

Substituted 1H-imidazoles

New substituted 1H-imidazoles and their salts, processes for the preparation thereof and pharmaceutical compositions. These compounds have the formula STR1 wherein R1, R2, R3 and R5 =hydrogen or C1 -C4 -alkyl; R4 =hydrogen, C1 -C4 -alkyl or C1 -C4 -alkoxy; Y1 =hydrogen and Y2 =OZ2 or the reverse; Z1 =Z2 =hydrogen or C1 -C4 -alkyl or Z1 and Z2 =--CH2 -- or --C(CH3)2 --. These compounds are prepared either by reducing a corresponding imidazole compound having a hydroxyl or alkoxy group on the methyl bridge between the imidazole and phenyl rings, or by hydrolyzing a 4-[[2,2-dimethyl-4H-1,3-benzodioxin-6(or 8)-yl]methyl]-1H-imidazole, or yet by reducing an alkyl 3-[(1H-imidazol-4-yl)methyl]-2-hydroxybenzoate. These compounds have cardiac, cerebral and tissular anti-ischemic activities.

ALPHA2-BLOCKING DERIVATIVES OF IMIDAZOLE

A compound of the formula: STR1 wherein X 1, X 2, Y 1 and Y 2, whether or not identical are hydrogen, a halogen such as fluoro, chloro or bromo, linear or branched alkyl of 1 to 3 carbon atoms, linear or branched alkoxy of 1 to 3 carbon atoms, carboxy, alkoxy-carbonyl of 1 to 3 carbon atoms or phenyl;R 1 is hydrogen, methyl or phenyl;R 2 and R 3, which may or may not be identical, are hydrogen, hydroxyl, linear or branched alkyl of 1 to 6 carbon atoms, or linear or branched alkoxy group of 1 to 4 carbon atoms;R 1 and R 2 may together form a carbon-carbon double bond; andR 4 and R 5 whether or not identical, are hydrogen, linear or branched alkyl or 1 to 3 carbon atoms.The compounds are useful as blocking agents of α 2-adrenergic receptors.